WasPart A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months, Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months., Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months, Part B:A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years, Part B:Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years;, Part B:No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until Cycle 2 Day 21, around 3 years.
NowPart A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months., Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months., Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months., Part B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years., Part B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years., Part B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until the end of the primary treatment period, around 3 years.